CYP3A4 and non-small cell lung carcinoma: Moreover, TKIs employed in the management of NSCLC, such as ceritinib, afatinib, cabozantinib, and crizotinib, have also been identified as inhibitors of CYP3A4 and P-gp, elevating the risk of pharmacokinetic DDIs.49